By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MorphoSys AG 

Lena-Christ-Strasse 48

Martinsried  Munich  82152  Germany
Phone: 49-0-89-899-27-0 Fax: 49-0-89-899-27-222


SEARCH JOBS


Industry
Biotechnology






Company News
MorphoSys AG's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study With Lanthipeptide MOR107 2/21/2017 9:01:34 AM
MorphoSys AG Release: Company Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients With Type 2 Diabetes 1/12/2017 9:45:16 AM
Dr. Malte Peters To Become New Chief Development Officer Of MorphoSys AG 1/5/2017 9:56:06 AM
MorphoSys AG To Present At Upcoming Investor Conferences 1/3/2017 8:46:41 AM
MorphoSys AG: Corporate Calendar 2017 12/15/2016 10:56:05 AM
MorphoSys AG Starts Phase 2 Trial Of MOR208 In Combination With Idelalisib In Patients With Relapsed Or Refractory CLL Or SLL Previously Treated With A BTK Inhibitor 12/13/2016 8:41:27 AM
MorphoSys AG Presents Updated Clinical Results For Anti-CD38 Antibody MOR202 At American Society of Hematology 2016 12/6/2016 9:56:36 AM
MorphoSys AG Presents Updated Clinical Data For Blood Cancer Candidate MOR208 In NHL And CLL At American Society of Hematology 2016 Conference 12/6/2016 9:51:48 AM
MorphoSys AG Announces That Its Licensee Janssen R&D Has Submitted A Marketing Authorization Application For Guselkumab In Europe 11/28/2016 9:27:51 AM
MorphoSys AG Announces That Its Licensee Janssen R&D Has Submitted Biologics License Application For Guselkumab 11/17/2016 10:08:21 AM
12345678910...
//-->